ATE278779T1 - ALPHAVIRUS RNA REPLICON SYSTEMS - Google Patents

ALPHAVIRUS RNA REPLICON SYSTEMS

Info

Publication number
ATE278779T1
ATE278779T1 AT96916547T AT96916547T ATE278779T1 AT E278779 T1 ATE278779 T1 AT E278779T1 AT 96916547 T AT96916547 T AT 96916547T AT 96916547 T AT96916547 T AT 96916547T AT E278779 T1 ATE278779 T1 AT E278779T1
Authority
AT
Austria
Prior art keywords
alphavirus
helper
rna
encoding
cell
Prior art date
Application number
AT96916547T
Other languages
German (de)
Inventor
Robert E Johnston
Nancy L Davis
Jonathan F Smith
Peter Pushko
Michael Parker
George Ludwig
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23781039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE278779(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE278779T1 publication Critical patent/ATE278779T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.
AT96916547T 1995-05-23 1996-05-21 ALPHAVIRUS RNA REPLICON SYSTEMS ATE278779T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/448,630 US5792462A (en) 1995-05-23 1995-05-23 Alphavirus RNA replicon systems
PCT/US1996/007454 WO1996037616A1 (en) 1995-05-23 1996-05-21 Alphavirus rna replicon systems

Publications (1)

Publication Number Publication Date
ATE278779T1 true ATE278779T1 (en) 2004-10-15

Family

ID=23781039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916547T ATE278779T1 (en) 1995-05-23 1996-05-21 ALPHAVIRUS RNA REPLICON SYSTEMS

Country Status (10)

Country Link
US (7) US5792462A (en)
EP (1) EP1012295B1 (en)
JP (1) JP3946768B2 (en)
AT (1) ATE278779T1 (en)
AU (1) AU727036C (en)
CA (1) CA2220964C (en)
DE (1) DE69633581T2 (en)
ES (1) ES2229269T3 (en)
PT (1) PT1012295E (en)
WO (1) WO1996037616A1 (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003978D0 (en) 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
DE19503082A1 (en) * 1995-02-01 1996-08-08 Univ Ludwigs Albert Subject and method for preferentially transient expression and possible translation of specific RNA in the cytoplasmic region of higher eukaryotic cells
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6097978A (en) * 1997-07-03 2000-08-01 Medtronic Inc. Measurement confirmation devices and methods for fluoroscopically directed surgery
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
CA2325564A1 (en) 1998-03-27 1999-10-07 Cytos Biotechnology Ag Inducible alphaviral gene expression system
DE69942006D1 (en) 1998-04-08 2010-03-25 Univ North Carolina CANCER VACCINATE CONTAINING ALPHAVIRUS REPLICON PARTICLES
US7267823B2 (en) * 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
CA2336554A1 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
US7736656B2 (en) * 1998-06-29 2010-06-15 The United States Of America As Represented By The Secretary Of The Army Immunogenic compositions and vaccines for Ebola
EP1097212B1 (en) * 1998-07-10 2008-12-24 U.S. Medical Research Institute of Infectious Diseases Anthrax vaccine
AU759461B2 (en) * 1998-07-10 2003-04-17 U.S. Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
US6770479B1 (en) 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
WO2000006205A1 (en) * 1998-07-29 2000-02-10 Invitrogen Corporation Regulated expression of recombinant proteins using rna viruses
ATE412434T1 (en) * 1998-11-30 2008-11-15 Cytos Biotechnology Ag MOLECULAR ARRANGEMENT OF ALLERGENS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US6423544B1 (en) 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
CA2359013C (en) 1998-12-31 2011-02-01 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
EP1035205A1 (en) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU4366000A (en) * 1999-04-14 2000-11-14 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001031046A1 (en) * 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
US20030170871A1 (en) * 2000-04-25 2003-09-11 Chiron Corporation Alphavirus-based vectors for persistent infection
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2001275191A1 (en) * 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002003917A2 (en) * 2000-07-07 2002-01-17 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
NZ523831A (en) * 2000-07-13 2005-10-28 Invitrogen Corp Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
KR100366624B1 (en) * 2000-07-19 2003-01-09 삼성전자 주식회사 Method for manufacturing semiconductor device using anti-reflective coating film
ES2454640T3 (en) * 2000-08-03 2014-04-11 Johns Hopkins University Molecular vaccine that carries a chaperone polypeptide from the endoplasmic reticulum to an antigen
AU2001293222B2 (en) * 2000-08-29 2007-09-20 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles
US6982087B2 (en) * 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
ES2359625T3 (en) 2000-12-28 2011-05-25 Wyeth Llc PROTECTIVE PROTEIN RECOMBINANT OF.
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
WO2002074920A2 (en) * 2001-03-16 2002-09-26 Johns Hopkins University A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
EP1432791B2 (en) * 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
MXPA04002644A (en) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof.
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
CA2461380C (en) * 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
WO2003048306A2 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
AU2003242742B2 (en) * 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004000872A2 (en) * 2002-06-21 2003-12-31 University Of North Carolina At Chapel Hill Improved alphavirus vectors having attenuated virion structural proteins
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
JP4726483B2 (en) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー Molecular antigen array
CA2487849A1 (en) * 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
DK1524994T3 (en) 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta 1-6 antigen arrays
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2004055166A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
CN1791678A (en) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 Improved alphavirus replicons and helper constructs
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US20070087331A1 (en) * 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
CA2527636A1 (en) 2003-05-29 2005-01-06 United States Army Medical Research Institute For Infectious Diseases, A Research Laboratory Owned And Operated By The United States Government A Live attenuated viral vaccines for eastern equine encephalitis virus
AU2004265232A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
US20060099587A1 (en) * 2003-06-20 2006-05-11 Johnston Robert E Alphavirus vectors having attentuated virion structural proteins
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
EP2311994A1 (en) * 2003-08-01 2011-04-20 Life Technologies Corporation Compositions and methods for preparing short RNA molecules and other nucleic acids
JP4668919B2 (en) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド Modified CEA / B7 vector
RU2006130006A (en) * 2004-01-20 2008-02-27 Цитос Биотехнологи Аг (Ch) GRAELIN CARRIER CONJUGATES
JP4805911B2 (en) * 2004-03-15 2011-11-02 ネクター セラピューティクス Polymeric compositions and complexes of HIV entry inhibitors
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
EP2811027A1 (en) * 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
EP1750761A1 (en) * 2004-06-02 2007-02-14 Cytos Biotechnology AG Medical uses of carrier conjugates of non-human tnf-peptides
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
WO2006091722A2 (en) * 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
NZ575476A (en) 2006-09-12 2012-07-27 Alphavax Inc Alphavirus replicon particles encoding il- 12 as immunological adjuvants
AU2007317347B2 (en) * 2006-11-03 2014-02-06 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
PL2947149T3 (en) 2007-06-21 2018-09-28 Alphavax, Inc. Alphavirus replicon particles for use in vaccination
CA2704153A1 (en) * 2007-09-26 2009-04-02 Vanderbilt University Vaccine for rsv and mpv
WO2009048633A2 (en) * 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
US8592205B2 (en) 2007-12-27 2013-11-26 Universitat Zurich Replication-defective arenavirus vectors
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
US20110229969A1 (en) * 2008-06-25 2011-09-22 Volker Sandig Cell Line for Propagation of Highly Attenuated AlphaViruses
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
ES2540958T3 (en) 2009-04-08 2015-07-15 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
EP2473525A4 (en) 2009-09-02 2013-08-21 Us Army Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
US8980284B2 (en) * 2010-01-25 2015-03-17 New York University Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
WO2012001196A2 (en) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Alphaviral vectors and the uses thereof for heterologous gene expression
SI3243526T1 (en) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
BR112013000244A2 (en) 2010-07-06 2016-05-17 Novartis Ag lipid liposomes having advantageous pka for administration of rna
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
ES2938866T3 (en) 2010-08-31 2023-04-17 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of RNA encoding immunogen
ES2716243T3 (en) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Antigen Supply Platforms
WO2012058073A2 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Methods and compositions to protect aquatic invertebrates from disease
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
EP2668201A2 (en) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunological compositions comprising hiv gp41 polypeptide derivatives
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013103434A1 (en) 2011-10-19 2013-07-11 Harrisvaccines, Inc. Methods and compositions to protect aquatic invertebrates from disease
US9506041B2 (en) 2012-03-26 2016-11-29 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Delivery of packaged RNA to mammalian cells
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
SG10201811190SA (en) 2013-12-16 2019-01-30 Us Health Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
WO2016094555A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
JP7250520B2 (en) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド Recombinant arterivirus replicon system and uses thereof
WO2018035311A1 (en) * 2016-08-19 2018-02-22 Gray John T Compositions and methods for modulating gene expression using reading frame surveillance
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
EA202091517A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV)
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
WO2019124441A1 (en) * 2017-12-20 2019-06-27 Vlp Therapeutics, Llc Alphavirus replicon particle
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
EP3796927A4 (en) * 2018-05-23 2022-04-20 Gritstone bio, Inc. Shared antigens
BR122024002387A2 (en) 2019-05-30 2024-03-12 Gritstone Bio, Inc. ADENOVIRUS VECTORS, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEOTIDE SEQUENCE, ISOLATED CELL, VECTOR, KIT, USES OF A VECTOR, METHOD FOR MAKING THE VECTOR, METHODS FOR PRODUCING A VIRUS AND VIRAL VECTOR
EP3986458A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
CN115768785A (en) * 2020-06-19 2023-03-07 英特维特国际股份有限公司 Swine influenza A virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding different neuraminidase antigens of the virus
WO2021255221A1 (en) * 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2023225637A1 (en) 2022-05-19 2023-11-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replicating rna vaccine for crimean-congo hemorrhagic fever virus

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (en) * 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JP2758826B2 (en) * 1994-03-02 1998-05-28 株式会社リコー Document search device
SE9401091D0 (en) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (en) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
CA2359013C (en) * 1998-12-31 2011-02-01 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
JP2000290187A (en) * 1999-04-05 2000-10-17 Toshio Sato Soft capsule filled with chitosan and its production
US6982087B2 (en) * 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86

Also Published As

Publication number Publication date
AU727036C (en) 2007-02-08
US6531135B1 (en) 2003-03-11
EP1012295A4 (en) 2000-12-06
WO1996037616A1 (en) 1996-11-28
EP1012295A1 (en) 2000-06-28
CA2220964A1 (en) 1996-11-28
US5792462A (en) 1998-08-11
US6541010B1 (en) 2003-04-01
PT1012295E (en) 2005-02-28
ES2229269T3 (en) 2005-04-16
EP1012295B1 (en) 2004-10-06
DE69633581T2 (en) 2005-10-13
US20010016199A1 (en) 2001-08-23
JPH11505719A (en) 1999-05-25
US6521235B2 (en) 2003-02-18
AU5925696A (en) 1996-12-11
US20030232036A1 (en) 2003-12-18
AU727036B2 (en) 2000-11-30
CA2220964C (en) 2011-09-13
JP3946768B2 (en) 2007-07-18
DE69633581D1 (en) 2004-11-11
US7235235B2 (en) 2007-06-26
US20040121466A1 (en) 2004-06-24
US6156558A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
DE69633581D1 (en) ALPHAVIRUS RNA REPLICON SYSTEMS
NO964862D0 (en) papillomavirus vaccines
WO1996030523A3 (en) Antigen presentation system based on retrovirus-like particles
DE68928638D1 (en) POLYETHYLENE GLYCOL (PEG) -PROTEIN ADDUCTS AND PROCESS FOR THEIR SEPARATION
DK0986361T3 (en) A new composite material and its application
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
GB9715660D0 (en) Proteins
CA2389518A1 (en) Inter-departmental mail sorting system and method
MX9708791A (en) Ataxia-telangiectasia gene and its genomic organization.
NO910982L (en) URATOXYDASE-ACTIVE PROTEIN, RECOMBINANT GENE CODING IT, EXPRESSION VECTOR, MICROORGANISMS AND TRANSFORMER CELLS.
GB0008411D0 (en) Pharmaceutical preparations and their manufacture
DE68911297D1 (en) HEPARIN-BINDING PROTEINS, CODING DNA, METHOD FOR THE PRODUCTION THEREOF AND THE THERAPEUTIC PREPARATIONS CONTAINING THEM.
WO1997045746A3 (en) Prion protein binding proteins and uses thereof
WO1996007739A3 (en) Interleukin-1 type 3 receptors
NO972063D0 (en) cDNA encoding a BMP type II receptor
AU6978096A (en) Dna encoding an sh2-inositol phosphatase, an shc-binding protein
WO1994016085A3 (en) Hybrid proteins having cross-linking and tissue-binding activities
DE59608073D1 (en) ANTIBODIES AGAINST A FUSION POLYPEPTIDE HAVING A HISTIDINE PART
CA2194032A1 (en) Fused dna sequence, fused protein expressed from said fused dna sequence and method for expressing said fused protein
NO974713L (en) Genes encoding lymphocyte interferon regulatory factor (LSIRF) polypeptides
EP0609292A4 (en) Soluble variants of type i membrane proteins, and methods of using them.
EP1181351A4 (en) Method of purifying heterologous proteins
ATE192163T1 (en) PEPTIDES, ANALOGUES AND THEIR MIXTURES FOR THE DETECTION AND GENERATION OF ANTIBODIES AGAINST THE E1 AND E2 PROTEINS OF THE RUBELLA VIRUS
WO1997016457A3 (en) Anti-tumoral protein
WO1997039623A3 (en) Improved production of insecticidal proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012295

Country of ref document: EP

REN Ceased due to non-payment of the annual fee